Halozyme Therapeutics (HALO) PT Raised to $22 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Halozyme Therapeutics (HALO) PT Raised to $19 at BMO Capital
February 21, 2018 8:42 AM ESTBMO Capital raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $19.00 (from $18.00) while maintaining a Market Perform rating.
Analyst Do Kim said they believe ENHANZE continues to provide a strong valuation floor with Janssen conducting six studies. However, PEGPH20 Phase III interim data in 4Q18 remains a key risk.
... MoreHalozyme Therapeutics (HALO) PT Raised to $24 at Deutsche Bank
February 21, 2018 6:55 AM ESTDeutsche Bank raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $24.00 (from $21.00) while maintaining a Buy rating following the company's 4Q earnings report. Results were in line with our expectations given the preliminary announcement of results earlier this year. +24.6% y/y royalty... More
Halozyme Therapeutics (HALO) PT Raised to $21 at Canaccord Genuity
February 21, 2018 5:12 AM ESTCanaccord Genuity raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $21.00 (from $19.00) while maintaining a Buy rating.
... MoreHalozyme Therapeutics (HALO) PT Raised to $21 at JMP Securities
February 21, 2018 4:34 AM ESTJMP Securities raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $21.00 (from $20.00) while maintaining a Market Outperform rating.
... MoreHalozyme Therapeutics (HALO) Tops Q4 EPS by 13c; Reiterates Outlook
February 20, 2018 4:07 PM ESTHalozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.85, $0.13 better than the analyst estimate of $0.72. Revenue for the quarter came in at $189.6 million versus the consensus estimate of $165.19 million.
Financial Outlook for 2018
Halozyme reiterated its financial guidance of:
Net revenue of $115 million to $125... More